FILING ANALYSIS · THURSDAY, NOVEMBER 19
PharmaCyte Biotech, Inc. PMCB — 8-K: Entry into a Material Definitive Agreement
neutral
PharmaCyte Biotech, Inc. exchanged 851,304 Series G Long-Term Warrants for 4,982,272 shares of Q/C Technologies, Inc. common stock, and also consented to extend the maturity date of Q/C's Series H Convertible Preferred Stock, which it holds a majority of, by six months to September 2, 2027, with no additional consideration paid, in a related-party deal with its CEO also serving as Q/C's CEO.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →